Clinical stage
Ambusol is pioneering therapies to eliminate residual glioblastoma (GBM) cells after surgery – and give patients new hope.
Ambusol is a clinical-stage cancer therapeutics company pioneering a patented approach to treat post-surgical Stage IV glioblastoma (GBM). Our mission is to eradicate residual cancer cells in the surgical margins and significantly improve patient outcome.
With 50 years of research from Uppsala Academic Hospital, we strive to offer groundbreaking treatment options for glioblastoma (GBM) that aim not only to extend patients’ lives but also to improve their quality of life. Through innovative approaches and a deep understanding of the complexity of the disease, we work tirelessly to create treatments that not only combat the disease but also promote well-being and recovery in our patients.
GBM therapy offers customized care and hope for a brighter future against glioblastoma (GBM).
Founded by the esteemed Professor Gunnar Ronquist, Ambusol emerged with an ambitious mission: to revolutionize the treatment of glioblastoma (GBM) and join the relentless battle against cancer. Our unwavering passion and dedication lie in developing a transformative therapy for GBM, relentlessly pursuing a deeper understanding of this formidable disease, and refining its management strategies. Through relentless innovation and unwavering research, we strive to offer hope and a brighter future for all those grappling with this debilitating illness.
Our unwavering commitment to developing effective therapies and our unwavering focus on driving meaningful change in the fight against GBM propel us to continuously challenge the frontiers of medical science and technology. We are driven by the profound belief that GBM, despite its formidable nature, can be effectively treated, and that our efforts can make a tangible difference in the lives of patients and their families.
Our lead compound is a non-physiological amino acid that selectively induces cytolysis (cell death) in highly malignant glioma cells by exploiting their metabolic vulnerabilities.
The TME is a critical driver of GBM progression, therapy resistance, and recurrence. One of its key components is extracellular vesicles (EVs), tiny particles that carry oncogenic proteins, RNA, and DNA to other cells, promoting tumor growth and immune evasion.
Our approach aims to disrupt this intercellular communication by:
We are developing a portable, implantable catheter-pump system to deliver the therapeutic agent directly into the post-surgical cavity, with:
This delivery platform ensures precision therapy exactly where it’s needed-with minimal systemic toxicity.
Note: These technologies are under development and intended for future clinical use in accordance with applicable regulations.